FIELD: pharmaceutics.
SUBSTANCE: invention relates to the use of therapeutically effective amount of a compound represented by the formula (I) or its pharmaceutically acceptable salt for the production of a drug for the treatment of pneumonia, while pneumonia is caused by infection with gram-negative bacteria, in particular Pseudomonas aeruginosa, a pharmaceutical composition, and a method for the treatment of such pneumonia.
EFFECT: treatment of pneumonia caused by infection with gram-negative bacteria, in particular Pseudomonas aeruginosa.
14 cl, 1 dwg, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | 2014 |
|
RU2686323C2 |
| BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773346C2 |
| COMPOUND WITH NEUROPROTECTOR ACTION, A METHOD OF ITS PRODUCTION AND ITS USE | 2020 |
|
RU2802457C1 |
| NOVEL COMPOUNDS AND FASN INHIBITION COMPOSITIONS | 2014 |
|
RU2737434C2 |
| TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | 2021 |
|
RU2815022C1 |
| PYRIMIDINE COMPOUND WITH CONDENSED RINGS, ITS INTERMEDIATE COMPOUND, METHOD OF PRODUCING, COMPOSITION AND USE | 2016 |
|
RU2732576C2 |
| MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2797558C2 |
| ERBB RECEPTOR INHIBITORS | 2019 |
|
RU2810215C2 |
| CALPAIN MODULATORS AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773288C2 |
| IMIDAZOPYRIDINE COMPOUNDS USEFUL IN TREATMENT OF CONDITION ASSOCIATED WITH P2X3 AND/OR P2X2/3 ACTIVITY | 2014 |
|
RU2656593C2 |
